Loading organizations...

Myopowers Medical Technologies is a technology company.
MyoPowers Medical Technologies develops implantable medical devices utilizing advanced artificial muscle technology. Their core product, ARTUS, is an innovative solution engineered to restore natural sphincter function, specifically targeting severe stress urinary incontinence. This unique technical approach provides crucial muscle assistance to patients facing profound medical challenges, particularly where conventional treatments fall short.
The company was founded in 2004 in Lausanne, Switzerland, by Dr. Piergiorgio Tozzi, MD, of the University Hospital of Lausanne, and Professor Daniel Hayoz. Their deep clinical and academic backgrounds provided the foundational insight into the significant unmet need for durable and effective interventions for individuals with muscle and sphincter deficiencies, driving the creation of their specialized technology.
MyoPowers' product serves patients, notably women, who suffer from severe stress urinary incontinence and currently have limited adequate treatment options. The company's vision centers on leveraging its sophisticated artificial muscle technology to restore natural bodily functions and substantially enhance the quality of life for those with critical medical needs, with potential future applications in other physiological systems.
Myopowers Medical Technologies has raised $21.0M across 2 funding rounds.
Myopowers Medical Technologies has raised $21.0M in total across 2 funding rounds.
Myopowers Medical Technologies has raised $21.0M in total across 2 funding rounds.
Myopowers Medical Technologies's investors include Earlybird Venture Capital, Philippe Pouletty, Blue Ocean Ventures, dRx Capital, Gran Plasa, Initiative Capital Romandie.
MyoPowers Medical Technologies is a medtech company specializing in innovative, minimally invasive medical devices for patients with deficient muscles or sphincters, particularly addressing structural heart diseases, mitral valve regurgitation, and severe stress urinary incontinence.[1][2] Its flagship product, ARTUS, is an adjustable artificial urinary sphincter that provides a lasting, non-surgical-adjustable solution for urological conditions, serving patients and healthcare providers in high-unmet-need areas like urology.[1][2] The company has raised $21.1M in total funding across 3 rounds, with the latest at $5.1M, indicating solid growth momentum in a competitive market alongside players like Zephyr Surgical Implants and Promedon.[1][2]
Founded in 2004, MyoPowers Medical Technologies began in Switzerland as a pioneer in artificial muscle technology to restore bodily functions impaired by weak sphincters or muscles.[1][2][4] It later relocated to France, operating from Besancon and St. Louis in the Alsace region, with early Swiss ties evident in its Lausanne address via c/o Bourgeois Avocats.[2][3] The idea emerged from targeting diseases with high unmet needs, leading to early traction through development of proprietary tech; pivotal moments include securing multiple funding rounds totaling over $20M, enabling commercialization of products like ARTUS for urinary incontinence.[1][2]
MyoPowers rides the wave of advancing minimally invasive medtech, particularly in urology and cardiology, where aging populations drive demand for sphincter and valve solutions amid rising urinary incontinence and heart disease prevalence.[1][2] Timing aligns with market growth—artificial urethra segments project expansion through 2026 across hospitals and clinics—fueled by forces like precision implants, regulatory tailwinds for adjustables, and post-pandemic medtech investment.[1] It influences the ecosystem by pushing boundaries in artificial muscle tech, fostering competition that elevates standards for patient outcomes in underserved areas.[1][4]
MyoPowers is poised for expansion via ARTUS commercialization and potential heart device pilots, leveraging its $21M funding to scale in Europe and beyond.[2] Trends like AI-enhanced implants and global urology demand will shape its path, potentially amplifying influence through partnerships or acquisitions in the $multi-billion medtech space.[1] As a nimble innovator, it could redefine sphincter treatments, circling back to its core mission of lasting relief for high-need patients.[2][4]
Myopowers Medical Technologies has raised $21.0M across 2 funding rounds. Most recently, it raised $5.0M Series C in June 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2015 | $5.0M Series C | Earlybird Venture Capital | |
| Jul 1, 2011 | $16.0M Series B | Philippe Pouletty | Earlybird Venture Capital, Blue Ocean Ventures, dRx Capital, Gran Plasa, Initiative Capital Romandie |